NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

Milestones achieved consolidate positioning in mitochondrial medicine

Six months (1 Jan. 2013 – 30 Jun. 2013)

  • Net revenues  were SEK 5,335,000 (0) and other operating income was SEK 863,000      (319,000).
  • Loss before tax was SEK -6,206,000 (-6,871,000).
  • Earnings per share* were SEK -0.39 (-0.41).
  • Diluted earnings  per share** were SEK -0.39 (-0.41).

Second quarter (1 Apr. 2013 – 30 Jun. 2013)

  • Net revenues were SEK 5,335,000 (0) and other operating income was SEK 159,000      (310,000).
  • Loss before tax was SEK -1,467,000 (-4,056,000).
  • Earnings per share* were SEK -0.15 (-0.24).
  • Diluted earnings per share** were SEK-0.15 (-0.24).

* Profit/loss for the period divided by the average number of shares before dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after dilution at the end of the period.

Business highlights in the second quarter of 2013

  • 10thof April, NeuroVive had its IPO on NASDAQ OMX Small Cap, with stock symbol NVP.

  • Patient 700 of totally 972 have been enrolled to its multinational phase III trial on the company’s pharmaceutical CicloMulsion® (CIRCUS trial) or treating reperfusion injury in myocardial infarction.

  • First patient have been enrolled to a clinical phase IIa trial on the company’s pharmaceutical NeuroSTAT® for treating traumatic brain damage. This trial covers a total of 20 patients and is being conducted at  the neurology clinic of the Danish National Hospital in Copenhagen.

  • In June, NeuroVive signed a collaboration agreement with Isomerase      Therapeutics to develop the molecules the company acquired from Biotica Ltd. in March 2013. The focus of this partnership is cell protection in traumatic brain damage, heart attack and in the new product segment of anti-viral      indications in the form of a new product designated NVP018/BC556.

  • NeuroVive’s subsidiary NeuroVive Pharmaceutical Asia Ltd. received      SEK 5.3 m(RMB 5 m) as a first milestone payment from NeuroVive’s collaboration partner in China, Sihuan Pharmaceutical.

Read the Interim Report here: NeuroVive Interim Report 2013-01-01_2013-06-30 


About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). www.neurovive.com